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Background: Blood eosinophil measurements may help to guide physicians on the use of 
inhaled corticosteroids (ICS) for patients with chronic obstructive pulmonary disease (COPD). 
Emerging data suggest that COPD patients with higher blood eosinophil counts may be at higher 
risk of exacerbations and more likely to benefit from combined ICS/long-acting beta
2
-agonist 
(LABA) treatment than therapy with a LABA alone. This analysis describes the distribution of 
blood eosinophil count at baseline in Japanese COPD patients in comparison with non-Japanese 
COPD patients.
Methods: A post hoc analysis of eosinophil distribution by percentage and absolute cell count 
was performed across 12 Phase II–IV COPD clinical studies (seven Japanese studies [N=848 
available absolute eosinophil counts] and five global studies [N=5,397 available eosinophil 
counts] that included 246 Japanese patients resident in Japan with available counts). Blood 
eosinophil distributions were assessed at baseline, before blinded treatment assignment.
Findings: Among Japanese patients, the median (interquartile range) absolute eosinophil count 
was 170 cells/mm3 (100–280 cells/mm3). Overall, 612/1,094 Japanese patients (56%) had an 
absolute eosinophil count $150 cells/mm3 and 902/1,304 Japanese patients (69%) had a percent-
age eosinophil $2%. Among non-Japanese patients, these values were 160 (100–250) cells/mm3, 
2,842/5,151 patients (55%), and 2,937/5,155 patients (57%), respectively. The eosinophil 
distribution among Japanese patients was similar to that among non-Japanese patients. Within 
multi-country studies with similar inclusion criteria, the eosinophil count was numerically lower 
in Japanese compared with non-Japanese patients (median 120 vs 160 cells/mm3).
Interpretation: The eosinophil distribution in Japanese patients seems comparable to that of 
non-Japanese patients; although within multi-country studies, there was a slightly lower median 
eosinophil count for Japanese patients compared with non-Japanese patients. These findings 
suggest that blood eosinophil data from global studies are of relevance in Japan.
Keywords: COPD, blood eosinophil count, percentage blood eosinophil, Japan
Introduction
Post hoc analyses of two clinical trials showed that there is evidence that a higher blood 
eosinophil count may be predictive of a higher risk of exacerbations for chronic obstruc-
tive pulmonary disease (COPD) patients with an exacerbation history who were treated 
with long-acting beta
2
-agonists (LABA), without inhaled corticosteroids (ICS).1,2 
Recent data suggest that patients with higher blood eosinophil levels may be more likely 
to benefit from combined ICS/LABA treatment than therapy with a LABA alone.1,3–7 
Moreover, the use of eosinophils as a potential biomarker to identify specific disease 
subtypes – or endotypes – for which treatment can be tailored to individual patients 
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has recently been discussed for COPD and other chronic lung 
conditions.8 For these reasons, blood eosinophil measure-
ments have the potential to help guide physicians on the use 
of ICS with regard to exacerbation prevention, but, as pointed 
out in the recent Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) guidelines, the data are not conclusive, 
and prospective clinical trials are needed before this can be 
recommended for daily clinical practice.9
Ethnicity has been reported to have little impact on 
eosinophil levels,10 but blood eosinophil levels can be 
elevated within and above the normal range in a number 
of conditions, including allergies and parasitic/fungal 
infections,11,12 and by external stimuli, such as smoking and 
exercise.13,14 However, blood eosinophil levels do not seem 
to be influenced by the use of ICS.15,16 As these external 
factors can vary between countries, it is possible that there 
may be differences in the distribution of eosinophil levels in 
patients with COPD between countries, although, in a post 
hoc analysis, the distribution of blood eosinophil counts in 
COPD patients in UK trials was similar to the distribution 
in patients from the rest of the world.17
As current evidence supports eosinophils as a potential 
biomarker, the primary objective of this analysis was to 
investigate the distribution of blood eosinophil counts at 
baseline in randomized, controlled trials recruiting Japanese 
patients with COPD and compare the eosinophil distribution 
at baseline in Japanese versus non-Japanese patients.
Methods
study design
A post hoc analysis of blood eosinophil distribution at base-
line was performed using data from the GlaxoSmithKline 
COPD clinical trial database. All individual trials examined 
in this post hoc analysis were approved by the appropriate 
regulatory organizations.
The inclusion criteria used to select studies for this analysis 
were any GlaxoSmithKline Research and Development or 
local GlaxoSmithKline-sponsored Phase II–IV randomized 
clinical trials conducted from 1999 to 2016 that recruited 
Japanese patients and included any of GSK961081, fluticasone 
furoate, fluticasone propionate, salmeterol, umeclidinium, 
vilanterol, alone, or as a dual combination as a randomized 
study drug for COPD, and for which individual patient baseline 
or screening blood eosinophil counts were available. As indi-
vidual patient data were not available in the published papers, 
non-GlaxoSmithKline and investigator-sponsored studies 
were not included. We also excluded studies reporting data 
from a single country only (outside Japan).
Across the individual studies included in this analysis, 
patient inclusion/exclusion criteria were mainly based on 
COPD diagnosis, forced expiratory volume in 1 second (FEV
1
) 
at entry, prior exacerbation history, previous/current diagnosis 
of asthma, smoking history, and reversible airflow limitation. 
None of the included studies used blood eosinophil count as 
an inclusion or exclusion criterion. A summary of the criteria 
for each trial is provided in Table S1 and further information 
on the designs of the trials is available on ClinicalTrials.gov.
The included studies were categorized into Japan-only 
studies and multi-country studies that recruited Japanese 
patients living in Japan. This is a post hoc analysis of study 
data, and, although the studies themselves all received ethical 
approval, the current analysis did not require additional 
ethical approval.
assessments
Blood samples for eosinophil assessments were taken 
according to routine laboratory screening as described 
in each individual study protocol. The earliest individual 
patient pre-randomization eosinophil values, prior to any 
ICS or oral corticosteroid run-in, were selected for use in 
the analysis, although not all patients were ICS naïve at the 
time of recruitment. Data on the number of patients who were 
not ICS naïve at the time of recruitment in each study or in 
each group were not available for inclusion in these analyses. 
Values were presented as absolute blood eosinophil counts 
and percentage blood eosinophils.
statistical analyses and data presentation
No formal statistical testing was performed. Japanese 
patient data from all of the studies were the primary 
focus of the analysis. Histograms of baseline eosinophil 
counts were produced. Summary tables of the proportion 
of patients by baseline absolute eosinophil subgroups 
(,100, $100; ,150, $150; ,300, $300 cells/mm3) and 
percentage eosinophil subgroups (,2%, $2%) were pro-
duced for Japanese patients only, both overall (Group 1: 
Japan-only studies combined with Japanese data from multi-
country studies) and by study.
A cumulative density function was produced to enable a 
visual comparison of the distribution of absolute eosinophils. 
A line for Group 1 and each of the four following groups 
was overlaid into a single plot; Group 2 – all patient data 
from Japan-only studies; Group 3 – all patient data from 
multi-country studies; Group 4 – Japanese patient data from 
multi-country studies; Group 5 – non-Japanese patient data 
from multi-country studies.
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Summary tables for Groups 1–5, based on absolute 
eosinophil count (,150, $150 cells/mm3) and percentage 
eosinophils (,2%, $2%), were also produced to compare 
baseline demographics and COPD disease characteristics 
(GOLD 2006 distribution [I–IV], St George’s Respiratory 
Questionnaire [SGRQ] score, and history of exacerbation). 
Data are presented from all Japanese patients (Group 1) 
alongside data from non-Japanese patients recruited to multi-
country studies (Group 5).
Results
Included studies
In total, 12 studies (seven Japan-only; five multi-country) 
met the inclusion criteria and were included in this 
analysis (Table S1). The seven Japan-only studies were: 
SCO100646 (NCT00269126), SCO100648 (NCT00269087), 
HZC114156 (NCT01192191), DB2115362 (NCT01376388), 
AC4115361 (NCT01702363), SCO116571 (NCT01607398),18 
and SCO116717 (COSMOS-J; NCT01762800).19 Study 
SCO116717 did not include data for absolute eosino-
phil count. The five multi-country studies included 
were: HZC112206 (NCT01053988),20 HZC112207 
(NCT01054885),19 DB2113361 (NCT01313637),21 
DB2113373 (NCT01313650), 22 and AC4115408 
(NCT01387230).23
Trial participants
Absolute blood eosinophil count data were available from 
6,245 trial participants, comprising 1,094 Japanese patients 
(848 from Japan-only studies; 246 from multi-country 
studies) and 5,151 non-Japanese patients from multi-country 
studies. Percentage blood eosinophil data were available from 
6,459 patients, comprising 1,304 Japanese patients (1,058 
from Japan-only studies; 246 from multi-country studies) 
and 5,155 non-Japanese patients.
Baseline demographics and disease characteristics of 
all Japanese patients and non-Japanese patients from multi-
country studies are shown in patients with available absolute 
blood eosinophil count in Table 1 and by percentage blood 
eosinophils and absolute eosinophils in Table S2. Baseline 
demographics and disease characteristics of patients in Japan-
only studies according to absolute eosinophils are shown in 
Table S3. Baseline characteristics were broadly comparable 
among Japanese and non-Japanese patients for most cat-
egories (Table 1), as well as comparable across percentage 
eosinophil subgroups (,2%, $2%) within each of these 
two patient groups (Table S2). However, a higher proportion 
of Japanese patients were male, $65 years of age, or were 
exacerbation-free in the 12 months prior to the study, compared 
with non-Japanese patients, and slightly more non-Japanese 
patients had GOLD stage III disease than Japanese patients 
(Tables 1 and S2). In addition, the SGRQ total score seemed 
lower in Japanese than in non-Japanese patients, although it 
should be noted that SGRQ data were only available for three 
of the multi-country studies, and patient numbers were low.
There was no apparent relationship between baseline 
eosinophil levels and exacerbation burden (Table S2), but 
no formal correlation analysis was performed.
Blood eosinophil distribution
A summary of absolute and percentage blood eosinophil 
counts in all five patient groups is shown in Table 2. Among 
Japanese patients, the median absolute blood eosinophil 
count was 170 cells/mm3, and 56% had an absolute blood 
eosinophil count $150 cells/mm3, with 69% having a 
percentage blood eosinophil $2%; among non-Japanese 
patients, these values were 160 cells/mm3, 55%, and 57%, 
respectively (Table 2).
The distribution of absolute blood eosinophil count 
among Japanese patients was comparable to the distribu-
tion among non-Japanese patients (Figure 1). However, the 
absolute blood eosinophil count was numerically lower in 
Japanese patients than in non-Japanese patients in the multi-
country studies (median 120 cells/mm3 vs 160 cells/mm3, 
respectively) (Table 2). The distributions of absolute blood 
eosinophil count and percentage blood eosinophils among 
all Japanese patients are shown in Figure 2A and B.
Discussion
The primary objective of the current analysis was to inves-
tigate the distribution of baseline blood eosinophil counts in 
Japanese COPD patients across GlaxoSmithKlineResearch 
and Development or local GlaxoSmithKline sponsored 
Phase II–IV randomized clinical trials of COPD therapies 
conducted from 1999 to 2016 that recruited Japanese patients 
and had available individual patient baseline/screening blood 
eosinophil counts. We also evaluated blood eosinophil dis-
tribution in non-Japanese COPD patients in multi-country 
studies. While no formal statistical testing was performed, 
we found that the distribution of absolute blood eosinophil 
counts in Japanese COPD patients across all studies was 
similar to the distribution in non-Japanese patients. However, 
when considering the multi-country studies only, the median 
blood eosinophil count was numerically lower in Japanese 
than in non-Japanese COPD patients. This difference may 
represent a more reliable reflection of the differences between 
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Japanese patients resident in Japan and non-Japanese patients 
recruited elsewhere in the world, as the inclusion criteria for 
Japanese and non-Japanese patients were the same within 
each multi-country trial. However, it should be noted that 
the sample size for this analysis was small.
One reason for the observed small difference in eosino-
phil count between Japanese and non-Japanese patients may 
be the differences in the way COPD patients are diagnosed in 
Western countries and in Japan. In Japan, there is a tendency 
to exclude patients with any features suggestive of asthma 
from a COPD diagnosis, and there is a lower diagnosis 
rate for COPD, especially in younger patients, with milder 
disease.24–27 Consistent with this, our analysis found that, 
compared with non-Japanese patients, a numerically higher 
proportion of Japanese patients overall and those in Japan-
only studies were older ($65 years), male, and with no 
recent history of exacerbations requiring corticosteroids and/
or antibiotics. The greater predominance of older Japanese 
male COPD patients is typical of other Japanese studies in 
clinical settings.26–28 However, the data from the Japanese 
Table 1 Patient demographics
Characteristics All studies, 
Japanese patients
(N=1,094)
Multi-country studies, 
non-Japanese patients
(N=5,151)
Multi-country studies, 
Japanese patients
(N=246)
age (years), mean (sD) 70 (7.4) 62 (8.7) 69 (7.4)
age (years), n (%)
,65
$65
257 (23)
837 (77)
3,029 (59)
2,122 (41)
68 (28)
178 (72)
Male, n (%) 1,037 (95) 3,454 (67) 234 (95)
gOlD stage, n (%)
n
I: FeV1 $80% predicted
II: 50% # FeV1 ,80% predicted
III: 30% # FeV1 ,50% predicted
IV: FeV1 ,30% predicted
1,042
1 (,1)
586 (56)
407 (39)
48 (5)
5,128
2 (,1)
2,370 (46)
2,263 (44)
493 (10)
245
0
141 (58)
83 (34)
21 (9)
sgrQ total score
n
Mean (sD)
156a
39.4 (15.64)
2,904a
48.9 (17.66)
156a
39.4 (15.64)
number of patients with COPD exacerbations managed 
without oral/systemic corticosteroids and/or antibiotics 
(not involving hospitalization) in the past 12 months, n (%)
n
0
1
2
.2
537b
523 (97)
14 (3)
0
0
2,140c
1,900 (89)
209 (10)
25 (1)
6 (,1)
89d
86 (97)
3 (3)
0
0
number of patients with COPD exacerbations requiring 
oral/systemic corticosteroids and/or antibiotics (not 
involving hospitalization) in the past 12 months, n (%)
n
0
1
2
.2
694e
612 (88)
59 (9)
15 (2)
8 (1)
5,151
3,822 (74)
1,034 (20)
199 (4)
96 (2)
246
217 (88)
20 (8)
4 (2)
5 (2)
number of patients with COPD exacerbations requiring 
hospitalization in the past 12 months, n (%)
n
0
1
2
.2
1,043f
1,008 (97)
33 (3)
2 (,1)
0
5,151
4,664 (91)
437 (8)
43 (,1)
7 (,1)
246
239 (97)
7 (3)
0
0
Notes: aavailable for studies aC4115408 (nCT01387230), DB2113361 (nCT01313637), and DB2113373 (nCT01313650) only. bavailable for studies aC4115361 
(nCT01702363), DB2115362 (nCT01376388), hZC112206 (nCT01053988), hZC112207 (nCT01054885), and hZC114156 (nCT01192191) only. cavailable for 
studies hZC112206 (nCT01053988 ), and hZC112207 (nCT01054885) only. dnot available for studies aC4115408 (nCT01387230), DB2113361 (nCT01313637), and 
DB2113373 (nCT01313650). enot available for studies sCO100646 (nCT00269126), sCO100648 (nCT00269087), and sCO116571 (nCT01607398). fnot available for 
study sCO116571 (nCT01607398).
Abbreviations: sD, standard deviation; gOlD, global Initiative for Chronic Obstructive lung Disease; FeV1, forced expiratory volume in 1 second; sgrQ, st george’s 
respiratory Questionnaire; COPD, chronic obstructive pulmonary disease.
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population in the current study show that, despite the exclu-
sion of patients with asthma, a proportion of patients have 
high eosinophil counts. Of note, one included study (the 
Japanese COSMOS-J trial; Table S1),18 of 400 patients with 
COPD, did not exclude patients with asthma.
Another possible reason for differences in eosinophil 
count between Japanese and non-Japanese patients may be 
due to local differences in the use of macrolides. Long-term 
prophylactic use of macrolides has been reported to reduce 
the frequency of exacerbations in patients with COPD,29 and 
macrolides can reduce eosinophil count.30 Unfortunately no 
data on the use of macrolides were available for patients in 
the included studies.
Data from two previous randomized, controlled trials 
indicate that patients with a blood eosinophil count $2% have 
a higher risk of exacerbation than patients with lower eosino-
phil levels.1,31 In the current analysis, there was no difference 
in the proportions of Japanese or non-Japanese patients with 
a prior history of COPD exacerbations between the ,2% and 
$2% eosinophil count subgroups. Blood eosinophil levels 
1.0
0.8
0.6
0.4
0.2
0
0 500 1,000 1,500 2,000
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Japan-only studies
Multi-country studies
Multi-country studies, Japan subjects
Multi-country studies, non-Japan subjects
All studies, Japan subjects
Figure 1 Japan-specific data distribution for absolute blood eosinophil count compared with other groups.
Notes: an empirical cumulative distribution function plot was produced to evaluate the distribution of absolute blood eosinophil count data, with a line for each of the 
five patient groups overlaid into a single plot. The lines show the cumulative probability for subjects in the specified group. Japan only studies: AC4115361 (NCT01702363), 
DB2115362 (nCT01376388), hZC114156 (nCT01192191), sCO100646 (nCT00269126), sCO100648 (nCT00269087), and sCO116571 (nCT01607398). The absolute 
eosinophil values were not available for the Japan-only study, sCO116717 (nCT01762800). Multi-country studies: aC4115408 (nCT01387230), DB2113361 (nCT01313637), 
DB2113373 (nCT01313650), hZC112206 (nCT01053988), and hZC112207 (nCT01054885).
Table 2 Summary of absolute and percentage blood eosinophil count across the five patient groups
All studies, 
Japanese patients
(n=1,094)
Japan-only 
studies
(n=848)
Multi-country 
studies
(n=5,397)
Multi-country studies, 
Japanese patients
(n=246)
Multi-country studies, 
non-Japanese patients
(n=5,151)
absolute blood eosinophil count, cells/mm3
Mean (sD)a 216.9 (192.09) 228.6 (191.70) 207.0 (207.53) 176.7 (188.34) 208.4 (208.31)
Median (IQr)a 170 (100–280) 180 (110–281) 160 (90–250) 120 (50–260) 160 (100–250)
,150 cells/mm3 (n [%]) 482 (44.1)b 343 (40.4)c 2,448 (45.4)d 139 (56.5)d 2,309 (44.8)d
$150 cells/mm3 (n [%]) 612 (55.9)b 505 (59.6)c 2,949 (54.6)d 107 (43.5)d 2,842 (55.2)d
Percentage blood eosinophil count
(n=1,304) (n=1,058) (n=5,401) (n=246) (n=5,155)
,2% eosinophils (n [%]) 402 (30.8)b 274 (25.9)c 2,346 (43.4)d 128 (52.0)d 2,218 (43.0)d
$2% eosinophils (n [%]) 902 (69.2)b 784 (74.1)c 3,055 (56.6)d 118 (48.0)d 2,937 (57.0)d
Notes: aJapan-only studies: aC4115361 (nCT01702363), DB2115362 (nCT01376388), hZC114156 (nCT01192191), sCO100646 (nCT00269126), sCO100648 
(nCT00269087), and sCO116571 (nCT01607398). study sCO116717 (nCT01762800) is Japan-only but absolute eosinophil values are not available. Multi-country 
studies: aC4115408 (nCT01387230), DB2113361 (nCT01313637,) DB2113373 (nCT01313650), hZC112206 (nCT01053988), and hZC112207 (nCT01054885). 
all studies: Japan-only studies and Multi-country studies combined. bstudies aC4115408 (nCT01387230), aC4115361 (nCT01702363), DB2113361 (nCT01313637), 
DB2113373 (nCT01313650), DB2115362 (nCT01376388), hZC112206 (nCT01053988), hZC112207 (nCT01054885), hZC114156 (nCT01192191), sCO100646 
(nCT00269126), sCO100648 (nCT00269087), and sCO116571 (nCT01607398) are included. For studies sCO100646 (nCT00269126), sCO100648 (nCT00269087), 
and SCO116571 (NCT01607398) subjects in FAS population are included. For percentage eosinophils, study SCO116717 (NCT01762800) was also included. cstudies 
aC4115361 (nCT01702363), DB2115362 (nCT01376388), hZC114156 (nCT01192191), sCO100646 (nCT00269126), sCO100648 (nCT00269087), and sCO116571 
(NCT01607398) are included. For studies SCO100646 (NCT00269126), SCO100648 (NCT00269087), and SCO116571 (NCT01607398) subjects in the full analysis 
set population are included. For percentage eosinophils, study sCO116717 (nCT01762800) was also included. dstudies aC4115408 (nCT01387230), DB2113361 
(nCT01313637), DB2113373 (nCT01313650), hZC112206 (nCT01053988), and hZC112207 (nCT01054885). are included.
Abbreviations: IQr, interquartile range; Fas, full analysis set; sD, standard deviation.
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have been proposed as a potential biomarker of responsive-
ness to ICS in patients with COPD.1–3 The $2% cutoff for 
raised eosinophil levels in COPD patients falls within what 
has traditionally been considered the normal range.32 While 
the purpose of the current analysis was not to examine asso-
ciations between ICS response and blood eosinophil counts 
in Japanese patients, the similar distributions observed in 
both Japanese and non-Japanese patients suggest that the 
same cutoff may be used in Japanese populations. However, 
this requires more formal testing in a comparative analysis of 
eosinophil response to ICS in Japanese patient populations.
A strength of the current analysis is that it included data 
from a relatively large sample of Japanese and non-Japanese 
patients across several studies. This may provide a more 
representative assessment of blood eosinophil levels than 
individual studies, as a variety of different studies with dif-
ferent inclusion criteria were included in the analysis. Fur-
thermore, the data from the multi-country studies allowed for 
a direct comparison of Japanese and non-Japanese patients in 
studies that used comparable inclusion/exclusion criteria and 
with measurements obtained over similar periods of time.
The current analysis was limited in that it was a post hoc 
analysis of several trials with no formal statistical analysis 
and not a single directly comparative, randomized, clinical 
trial. The trials also included patients with a wide range 
of COPD severity and inflammatory conditions. Previous 
studies have indicated that combined ICS/LABA therapy 
may benefit COPD patients with higher eosinophil counts.1,3–7 
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Figure 2 Distribution of (A) absolute blood eosinophil count and (B) percentage blood eosinophils among Japanese patients with COPD.
Notes: (A) Subjects with eosinophil values .800 cells/mm3 are grouped together in the .800 bar. For studies sCO100646 (nCT00269126), sCO100648 (nCT00269087), 
and SCO116571 (NCT01607398), subjects in full analysis set population are included. (B) Subjects with eosinophil values .14% are grouped together in the .14 bar. For 
studies SCO100646 (NCT00269126), SCO100648 (NCT00269087), and SCO116571 (NCT01607398), subjects in full analysis set population are included. (B) Subjects with 
eosinophil values .14% are grouped together in the >14 bar. For studies sCO100646 (nCT00269126), sCO100648 (nCT00269087), and sCO116571 (nCT01607398), 
subjects in the full analysis set population are included. For study SCO116717 (NCT01762800), subjects in the modified ITT population are included.
Abbreviations: COPD, chronic obstructive pulmonary disease; ITT, intention-to-treat.
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Blood eosinophil distributions in Japanese COPD patients
However, the current study populations mainly comprised 
patients with infrequent exacerbations and so may not be 
directly comparable to the populations examined in previous 
studies. Eosinophil counts may be influenced by smoking 
history and body mass index, but data on these variables were 
not available in all trials included in the analysis. A further 
study limitation is that the clinical diagnosis of COPD used to 
identify patients for inclusion into these trials was at the dis-
cretion of the investigator at the study site, as such there may 
be differences in the patient characteristics between Japan and 
other countries. As with all data obtained from randomized, 
controlled trials with stringent eligibility criteria, the current 
data may also not be truly generalizable to the wider popula-
tion of COPD patients in Japan. Not all of the factors that 
can affect eosinophil cell distribution were investigated, nor 
were those that can affect eosinophil level (eg, comorbidity, 
atopy) in each study considered in a statistical manner. 
Finally, this analysis provides no measure of the stability of 
blood eosinophil levels in Japanese patients. Despite these 
limitations, the outcomes of this analysis suggest that blood 
eosinophil measurements are potential predictors of ICS 
responsiveness in COPD in Japanese patients.
Conclusion
Overall, the distribution of blood eosinophil counts in 
Japanese patients seems comparable with that of non-
Japanese patients; although there was a slightly lower median 
eosinophil count for Japanese patients in multi-country 
studies compared with non-Japanese patients in the same 
studies. The current post hoc analysis provides support for 
further exploration of the utility of blood eosinophil counts in 
Japanese patients. Prospective studies examining the predic-
tive validity of blood eosinophil counts as a marker of ICS 
responsiveness in Japanese COPD patients are warranted.
Previous presentation of data
These data were presented at a scientific meeting, the Japanese 
Respiratory Society 2017, held between 21 and 23 April, in 
a presentation: “Blood eosinophil levels in Japanese COPD 
patients” by Takeo Ishii, Dawn Midwinter, Mark James, 
Emma Hilton, Paul Jones, and Neil Barnes.
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